Press release
Irritable Bowel Syndrome (IBS) Treatment Market Expects to See Significant Growth During -2028
The Irritable Bowel Syndrome (IBS) Treatment Market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.The factors such as increasing prevalence of irritable bowel syndrome (IBS) diseases and rising research & development activities drive the market growth. Moreover, product innovations are expected to foster the market growth during the forecast period. However, the limited number of product availability and treatment inefficiency hinder the growth of the irritable bowel syndrome (IBS) treatment market. Additionally, in North America, medical device companies are finding difficulties in managing their operations due to the ongoing COVID-19 pandemic. Research studies published in Wolters Kluwer Health, Inc. (a US-based global leader in professional information, software solutions, and services for the health) stated that the COVID-19 pandemic is related to self-reported increases in psychological distress and gastrointestinal symptoms among individuals with IBS and comorbid anxiety or/and depression.
Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00083698?utm_source=OpenPr&utm_medium=10640
Analysis of the Top Market Players:
1. Ironwood Pharmaceuticals, Inc.
2. AbbVie.
3. Sebela Pharmaceuticals, Inc.
4. Takeda Pharmaceutical Company Limited
5. Alfasigma S.p.A.
6. Astellas Pharma Inc.
7. AstraZeneca
8. Synthetic Biologics, Inc.
9. Bausch + Lomb Incorporated
10. Lannett Company Inc
In this report, the market has been segmented on the basis of:
Type [IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C)
Mixed IBS (IBS-M)], Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others)
Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)
Get full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/irritable-bowel-syndrome-ibs-treatment-market
The global irritable bowel syndrome (IBS) treatment market is segmented on the basis of type, product, and distribution channel. Based on type, the market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). The mixed IBS (IBS-M) segment held the largest share of the market in 2020 and is anticipated to register the highest CAGR during 2021-2028. The irritable bowel syndrome (IBS) treatment market, based on product, is segmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. The linaclotide segment held the largest share of the market in 2020. Also, the same segment is estimated to register the highest CAGR in the market during the forecast period. Based on distribution channel, the market is segmented into hospitals pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospitals pharmacies segment held the largest market share in 2020. However, the drug stores and retail pharmacies segment is estimated to register the highest CAGR during the forecast period.
Buy this research report at @: https://www.premiummarketinsights.com/buy/TIP00083698?utm_source=OpenPr&utm_medium=10640
Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com
About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome (IBS) Treatment Market Expects to See Significant Growth During -2028 here
News-ID: 3691851 • Views: …
More Releases from Premium Market Insights
The Future of HVAC: Trends and Innovations
The Europe HVAC System Market HVAC system market was valued at US$ 50,772.07 million in 2022 and is expected to reach US$ 1,25,024.86 million by 2030; it is estimated to grow at a CAGR of 11.9% from 2022 to 2030.
𝐆𝐫𝐚𝐛 𝐏𝐃𝐅 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞➜ https://www.businessmarketinsights.com/sample/BMIRE00026922?utm_source=OpenPR&utm_medium=10694
Rise in Demand for Energy-Efficient Solutions Fuel the Europe HVAC System Market
Greenhouse gases are the primary sources of global warming and climate change. These gases absorb…
Automated External Defibrillators Market New Business Opportunities and Investme …
The Automated External Defibrillators Market is estimated to reach US$ 2,207.94 million in 2030 from US$ 1,556.21 million by 2030; the market is projected to record a CAGR of 4.5% from 2022 to 2030.
Some of the key driving factors for the automated external defibrillators market growth are the increasing prevalence of cardiovascular diseases and rising training and awareness programs on automated external defibrillators. However, performance issues related to automated external…
Hydrolyzed Collagen Market Types and Applications, Industry Drivers, Future Dema …
The Hydrolyzed Collagen Market was valued at US$ 946.43 million in 2022 and is projected to reach US$ 1,322.60 million by 2028; it is expected to register a CAGR of 5.7% from 2022 to 2028.
Various end-use industries are adopting business expansion strategies and scaling production capacity to provide better customer satisfaction. For instance, in July 2020, Rousselot and Giusto Faravelli announced a distribution partnership in Italy, effective from October 2020.…
Aroma Ingredients Market Expectations & Growth, Trends Highlighted Until 2028
The Aroma Ingredients Market was valued at US$ 5376.90 million in 2021 and is projected to reach US$ 7692.62 million by 2028; it is expected to grow at a CAGR of 5.2% from 2021 to 2028.
Aroma ingredients are basically isolates of naturally sourced ingredients or chemically produced and are used as ingredients to add aromas or fragrance to various cosmetic and personal care products.
Based on product type, the global aroma…
More Releases for IBS
Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs.
👉 Download our latest market insights:…
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR…
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA…
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide.
A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L…
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning.
This also includes consulting services concerning railway systems issues, such as travel…
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011.
The new bulkers, each with a capacity of 176,000 dwt, will be equipped…